Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM

Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and expert-led discussions, you’ll be empowered to manage complex treatment scenarios, deliver comprehensive patient education, and navigate even the trickiest treatment-related challenges.

On May 15, 2024 (after the recording of this activity), the FDA has granted accelerated approval for lisocabtagene maraleucel, a CAR T-cell therapy, for the treatment of adult patients with R/R FL who have received two or more prior lines of systemic therapy.

On May 30, 2024 (after the recording of this activity), the FDA has granted accelerated approval for lisocabtagene maraleucel, a CAR T-cell therapy, for the treatment of adult patients with R/R MCL who have received after at least 2 lines of systemic therapy, including a BTK inhibitor.